-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau says FDA approves IDE supplement expanding pancreatic cancer IMPACT trial

PUBT·04/23/2026 13:08:11
Listen to the news
Alpha Tau says FDA approves IDE supplement expanding pancreatic cancer IMPACT trial
  • Alpha Tau Medical received FDA clearance for an IDE supplement expanding its U.S. IMPACT pancreatic cancer pilot study of Alpha DaRT combined with chemotherapy.
  • Trial now adds gemcitabine with Abraxane as an eligible regimen.
  • Planned enrollment increases to 40 patients from 30.
  • Alpha Tau now expects recruitment to finish in Q3 2026, versus prior Q2 2026 timing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230902PRIMZONEFULLFEED9695813) on April 23, 2026, and is solely responsible for the information contained therein.